Explore

Trendline Trendline
Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Inhibitor Development

Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Inhibitor Development

Eli Lilly Ends Partnership with Rigel Pharmaceuticals, Impacting RIPK1 Inhibitor Development
Trendline Trendline
Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions

Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions

Roche's Fenebrutinib Shows Promise in Reducing MS Relapses and Brain Lesions
Trendline Trendline
Gilead and Arcus Discontinue TIGIT Drug Trials Due to Futility in Lung Cancer Study

Gilead and Arcus Discontinue TIGIT Drug Trials Due to Futility in Lung Cancer Study

Gilead and Arcus Discontinue TIGIT Drug Trials Due to Futility in Lung Cancer Study
Trendline Trendline
Gilead and Arcus End Cancer Drug Trials Following Futility Analysis

Gilead and Arcus End Cancer Drug Trials Following Futility Analysis

Gilead and Arcus End Cancer Drug Trials Following Futility Analysis
Trendline Trendline
Eli Lilly Expands Cancer Treatment Portfolio with Kelonia Acquisition

Eli Lilly Expands Cancer Treatment Portfolio with Kelonia Acquisition

Eli Lilly Expands Cancer Treatment Portfolio with Kelonia Acquisition
Trendline Trendline
Pfizer's New GLP-1 Drug Could Disrupt Lilly and Novo's Weight Loss Market

Pfizer's New GLP-1 Drug Could Disrupt Lilly and Novo's Weight Loss Market

Pfizer's New GLP-1 Drug Could Disrupt Lilly and Novo's Weight Loss Market
Trendline Trendline
Merck Shares Decline Following Unsuccessful Kidney Cancer Drug Trial

Merck Shares Decline Following Unsuccessful Kidney Cancer Drug Trial

Merck Shares Decline Following Unsuccessful Kidney Cancer Drug Trial
Trendline Trendline
Eli Lilly Expands Cancer Treatment Portfolio with Acquisition of Kelonia Therapeutics

Eli Lilly Expands Cancer Treatment Portfolio with Acquisition of Kelonia Therapeutics

Eli Lilly Expands Cancer Treatment Portfolio with Acquisition of Kelonia Therapeutics
Trendline Trendline
AstraZeneca's Tozorakimab Shows Promise in COPD Phase 3 Trials, Paving Way for Market Entry

AstraZeneca's Tozorakimab Shows Promise in COPD Phase 3 Trials, Paving Way for Market Entry

AstraZeneca's Tozorakimab Shows Promise in COPD Phase 3 Trials, Paving Way for Market Entry
Trendline Trendline
Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics

Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics

Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics
Trendline Trendline
Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment

Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment

Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment
Trendline Trendline
UCB Acquires Neurona Therapeutics in $1.15 Billion Deal to Advance Epilepsy Treatment

UCB Acquires Neurona Therapeutics in $1.15 Billion Deal to Advance Epilepsy Treatment

UCB Acquires Neurona Therapeutics in $1.15 Billion Deal to Advance Epilepsy Treatment